Latest news with #AyaHealthcare
Yahoo
12 hours ago
- Business
- Yahoo
Aya Healthcare acquires Locum's Nest to enhance NHS staffing solutions
Aya Healthcare has acquired Locum's Nest, a UK-based workforce solutions provider that connects healthcare professionals with available shifts in National Health Service (NHS) hospitals through a mobile application. Founded by Drs Nicholas Andreou and Ahmed Shahrabani in 2016, Locum's Nest was established to streamline the process of filling vacant shifts in NHS hospitals with qualified healthcare professionals. The company developed a cloud-based platform featuring a managed float pool system covering several hospitals and regions. Locum's Nest will continue to operate under its own brand identity. Aya Healthcare CEO Emily Hazen said: 'We are excited to welcome Locum's Nest to the Aya family of brands and are energised by the opportunity to transform healthcare staffing around the world through innovation, technology and purpose.' Locum's Nest serves as a technology partner for the NHS and focuses on improving the working conditions and overall experience of the contingent workforce. Its float pool system enables NHS Trusts to share workforce resources, promoting cost-effectiveness while supporting staff with suitable shift arrangements. Dr Andreou said: 'We're thrilled to partner with Aya in advancing our collective mission to improve healthcare worldwide. 'Aya's resources and expertise will help us grow faster, innovate more boldly, and ultimately make a greater difference.' Aya Healthcare, a healthcare staffing and talent software company in the US, operates a comprehensive digital staffing platform that offers various healthcare labour services. The services include allied health, interim leadership, locum tenens, non-clinical roles, per diem staffing, permanent hiring, and travel nursing. In December 2024, Aya Healthcare announced the acquisition of workforce solutions advisory company Cross Country Healthcare for approximately $615m. "Aya Healthcare acquires Locum's Nest to enhance NHS staffing solutions" was originally created and published by Hospital Management, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Business Wire
07-05-2025
- Business
- Business Wire
Cross Country Healthcare Announces First Quarter 2025 Financial Results
BOCA RATON, Fla.--(BUSINESS WIRE)--Cross Country Healthcare, Inc. (the Company) (Nasdaq: CCRN) today announced financial results for its first quarter ended March 31, 2025. SELECTED FINANCIAL INFORMATION: Variance Variance Q1 2025 vs Q1 2025 vs Dollars are in thousands, except per share amounts Q1 2025 Q1 2024 Q4 2024 Revenue $ 293,408 (23 ) % (5 ) % Gross profit margin* 20.0 % (40 ) bps — bps Net loss attributable to common stockholders $ (490 ) (118 ) % 87 % Diluted EPS $ (0.02 ) $ (0.10 ) $ 0.10 Adjusted EBITDA* $ 8,619 (44 ) % (7 ) % Adjusted EBITDA margin* 2.9 % (110 ) bps (10 ) bps Adjusted EPS* $ 0.06 $ (0.13 ) $ 0.02 Cash flows provided by operations $ 5,681 (5 ) % (77 ) % * Represents amounts that are not calculated in accordance with U.S. generally accepted accounting principles (GAAP) and are referred to as non-GAAP measures. Please refer to the accompanying discussion below of how these non-GAAP financial measures are calculated and used under 'Non-GAAP Financial Measures' and the tables reconciling these measures to the closest GAAP measure. Expand First Quarter Business Highlights Homecare Staffing experienced double-digit sequential and year-over-year revenue growth Physician Staffing experienced year-over-year revenue growth Cross Country Education experienced double-digit sequential revenue growth Continued strong balance sheet with $81 million of cash on hand and no debt as of March 31, 2025 'Our first quarter results reflect solid execution with both Homecare and Physician Staffing business reporting solid year over year growth,' said John A. Martins, President and Chief Executive Officer of Cross Country Healthcare. He continued, 'As the market for core nurse and allied continues to stabilize, we remain focused on driving productivity across our business, leveraging our investments in AI automation as well as our cost-effective center of excellence in India to fuel efficiency and improved profitability. Looking ahead, we continue working with Aya Healthcare and the Federal Trade Commission towards the successful consummation of the merger transaction in the second half of this year.' Regarding the Company's pending acquisition by Aya Healthcare, Martins further commented, 'We recently learned of the passing of Alan Braynin, founder, former CEO & President of Aya Healthcare, and our hearts go out to his family, friends and to the thousands of Aya employees. Alan was a pioneer and transformational force in the healthcare staffing industry whose presence will be missed by many.' First quarter consolidated revenue was $293.4 million, a decrease of 23% year-over-year and 5% sequentially. Consolidated gross profit margin was 20.0%, down 40 basis points year-over-year and flat sequentially. Net loss attributable to common stockholders was $0.5 million, as compared to net income of $2.7 million in the prior year and a net loss of $3.8 million in the prior quarter. Diluted earnings per share (EPS) was a net loss of $0.02, as compared to net income of $0.08 in the prior year and a net loss of $0.12 in the prior quarter. Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) was $8.6 million, or 2.9% of revenue, as compared with $15.3 million, or 4.0% of revenue, in the prior year, and $9.3 million, or 3.0% of revenue, in the prior quarter. Adjusted EPS was $0.06, as compared to $0.19 in the prior year and $0.04 in the prior quarter. Quarterly Business Segment Highlights Nurse and Allied Staffing Revenue was $242.3 million, a decrease of 27% year-over-year and 6% sequentially. Contribution income was $17.2 million, as compared to $27.2 million in the prior year and $20.3 million in the prior quarter. Average field contract personnel on a full-time equivalent (FTE) basis was 7,411, as compared with 9,124 in the prior year and 7,621 in the prior quarter. Revenue per FTE per day was $360, as compared to $397 in the prior year and $363 in the prior quarter. Physician Staffing Revenue was $51.1 million, an increase of 9% year-over-year and a decrease of 4% sequentially. Contribution income was $4.0 million, as compared to $3.1 million in the prior year and $3.5 million in the prior quarter. Total days filled were 22,692, as compared with 23,785 in the prior year and 25,427 in the prior quarter. Revenue per day filled was $2,253, as compared with $1,976 in the prior year and $2,085 in the prior quarter. Cash Flow and Balance Sheet Highlights Net cash provided by operating activities for the three months ended March 31, 2025 was $5.7 million, as compared to $6.0 million for the three months ended March 31, 2024 and $24.2 million for the three months ended December 31, 2024. We experienced a 15-day year-over-year improvement in days' sales outstanding. During the first quarter of 2025, the Company did not repurchase any shares of its common stock. As of March 31, 2025, the Company had 32.5 million unrestricted shares outstanding and $40.5 million remaining for share repurchase. As of March 31, 2025, the Company had $80.7 million in cash and cash equivalents with no debt outstanding. There were no borrowings drawn under its revolving senior secured asset-based credit facility (ABL). As of March 31, 2025, borrowing base availability under the ABL was $148.4 million, with $133.5 million of availability net of $14.9 million of letters of credit. CONFERENCE CALL As previously disclosed, on December 3, 2024, the Company entered into a merger agreement with Aya Healthcare, Inc. and certain of its subsidiaries (Aya Merger, and such agreement, the Merger Agreement). In light of the pending transaction, the Company will not host an earnings conference call to review first quarter 2025 financial results, nor will it provide forward-looking guidance. This press release is also posted on the Company's website at ABOUT CROSS COUNTRY HEALTHCARE Cross Country Healthcare, Inc. is a market-leading, tech-enabled workforce solutions and advisory firm with 39 years of industry experience and insight. We help clients tackle complex labor-related challenges and achieve high-quality outcomes, while reducing complexity and improving visibility through data-driven insights. Copies of this and other press releases, information about the Company, as well as information about the Aya Merger, can be accessed online at Stockholders and prospective investors can also register to automatically receive the Company's press releases, filings with the Securities and Exchange Commission (SEC), and other notices by e-mail. NON-GAAP FINANCIAL MEASURES This press release and the accompanying financial statement tables reference non-GAAP financial measures, such as gross profit margin, adjusted EBITDA, adjusted EBITDA margin, and adjusted EPS. Such non-GAAP financial measures are provided as additional information and should not be considered substitutes for, or superior to, financial measures calculated in accordance with GAAP. Such non-GAAP financial measures are provided for consistency and comparability to prior year results; furthermore, management believes such non-GAAP financial measures are useful to investors when evaluating the Company's performance, as such non-GAAP financial measures exclude certain items that management believes are not indicative of the Company's future operating performance. Pro forma measures, if applicable, are adjusted to include the results of our acquisitions, and exclude the results of divestments, as if the transactions occurred in the beginning of the periods mentioned. Such non-GAAP financial measures may differ materially from the non-GAAP financial measures used by other companies. The financial statement tables that accompany this press release include a reconciliation of each non-GAAP financial measure to the most directly comparable GAAP financial measure and a more detailed discussion of each financial measure; as such, the financial statement tables should be read in conjunction with the presentation of these non-GAAP financial measures. FORWARD-LOOKING STATEMENTS This press release contains 'forward-looking statements' within the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that are not statements of historical fact, including statements relating to our future results (including business trends); statements regarding the proposed Aya Merger; the expected timing and closing of the proposed Aya Merger; the Company's ability to consummate the proposed Aya Merger; the expected benefits of the proposed Aya Merger and other considerations taken into account by the Board in approving the proposed Aya Merger; the amounts to be received by stockholders in connection with the proposed Aya Merger; and expectations for the Company prior to and following the closing of the proposed Aya Merger, may be deemed to be forward-looking statements. All such forward-looking statements are intended to provide management's current expectations for the future of the Company based on current expectations and assumptions relating to the Company's business, the economy and other future conditions. Forward-looking statements generally can be identified through the use of words such as 'believes,' 'anticipates,' 'may,' 'should,' 'will,' 'plans,' 'projects,' 'expects,' 'expectations,' 'estimates,' 'forecasts,' 'predicts,' 'targets,' 'prospects,' 'strategy,' 'signs,' and other words of similar meaning in connection with the discussion of future performance, plans, actions or events. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and changes in circumstances that are difficult to predict. Such risks and uncertainties include, among others: (i) the timing to consummate the proposed Aya Merger, (ii) the risk that a condition of closing of the proposed Aya Merger may not be satisfied or that the closing of the proposed Aya Merger might otherwise not occur, (iii) the risk that a regulatory approval that may be required for the proposed Aya Merger is not obtained or is obtained subject to conditions that are not anticipated, (iv) the diversion of management time on transaction-related issues, (v) risks related to disruption of management time from ongoing business operations due to the proposed Aya Merger, (vi) the risk that any announcements relating to the proposed Aya Merger could have adverse effects on the market price of the common stock of the Company, (vii) the risk that the proposed Aya Merger and its announcement could have an adverse effect on the ability of the Company to retain customers and retain and hire key personnel and maintain relationships with its suppliers and customers, (viii) the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the Merger Agreement, including in circumstances requiring the Company to pay a termination fee, (ix) the risk that competing offers will be made, (x) unexpected costs, charges or expenses resulting from the Aya Merger, (xi) potential litigation relating to the Aya Merger that could be instituted against the parties to the Merger Agreement or their respective directors, managers or officers, including the effects of any outcomes related thereto, (xii) worldwide economic or political changes that affect the markets that the Company's businesses serve which could have an effect on demand for the Company's services and impact the Company's profitability, (xiii) effects from global pandemics, epidemics or other public health crises, (xiv) changes in marketplace conditions, such as alternative modes of healthcare delivery, reimbursement and customer needs, and (xv) disruptions in the global credit and financial markets, including diminished liquidity and credit availability, changes in international trade agreements, including tariffs and trade restrictions, cyber-security vulnerabilities, foreign currency volatility, swings in consumer confidence and spending, costs of providing services, retention of key employees, and outcomes of legal proceedings, claims and investigations. Accordingly, actual results may differ materially from those contemplated by these forward-looking statements. Investors, therefore, are cautioned against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with the SEC, including the risks and uncertainties identified in Part I, Item 1A - Risk Factors of the Company's Annual Report on Form 10-K for the year ended December 31, 2024, as amended by Amendment No. 1 on Form 10-K/A, and in the Company's other filings with the SEC. The list of factors is not intended to be exhaustive. These forward-looking statements speak only as of the date of this press release, and the Company does not assume any obligation to update or revise any forward-looking statement made in this press release or that may from time to time be made by or on behalf of the Company. Cross Country Healthcare, Inc. Reconciliation of Non-GAAP Financial Measures (Unaudited, amounts in thousands, except per share data) Three Months Ended March 31, March 31, December 31, 2025 2024 2024 Adjusted EBITDA: a Net (loss) income attributable to common stockholders $ (490 ) $ 2,692 $ (3,753 ) Interest expense 543 462 608 Income tax (benefit) expense (409 ) 997 (161 ) Depreciation and amortization 4,772 4,642 4,341 Acquisition and integration-related costs b 2,041 — 4,216 Restructuring costs c 301 938 281 Legal, bankruptcy, and other losses (gains) d — 3,650 (928 ) Impairment charges e — 604 2,170 Loss on disposal of fixed assets — — 86 Interest income f (681 ) (173 ) (535 ) Other expense (income), net 60 (1,057 ) 322 Equity compensation 1,318 1,198 1,698 System conversion costs g 1,164 1,329 926 Adjusted EBITDA a $ 8,619 $ 15,282 $ 9,271 Adjusted EBITDA margin a 2.9 % 4.0 % 3.0 % Adjusted EPS: h Numerator: Net (loss) income attributable to common stockholders $ (490 ) $ 2,692 $ (3,753 ) Non-GAAP adjustments - pretax: Acquisition and integration-related costs b 2,041 — 4,216 Restructuring costs c 301 938 281 Legal, bankruptcy, and other losses (gains) d — 3,650 (928 ) Impairment charges e — 604 2,170 Other (income) expense, net — (1,115 ) 311 System conversion costs g 1,164 1,329 926 Tax impact of non-GAAP adjustments (919 ) (1,405 ) (1,843 ) Adjusted net income attributable to common stockholders - non-GAAP $ 2,097 $ 6,693 $ 1,380 Denominator: Dilutive impact of share-based payments 281 381 68 Adjusted weighted average common shares - diluted, non-GAAP 32,563 34,597 32,406 Reconciliation: Diluted EPS, GAAP $ (0.02 ) $ 0.08 $ (0.12 ) Non-GAAP adjustments - pretax: Acquisition and integration-related costs b 0.06 — 0.13 Restructuring costs c 0.01 0.02 0.01 Legal, bankruptcy, and other losses (gains) d — 0.10 (0.03 ) Impairment charges e — 0.02 0.07 Other (income) expense, net — (0.03 ) 0.01 System conversion costs g 0.04 0.04 0.03 Tax impact of non-GAAP adjustments (0.03 ) (0.04 ) (0.06 ) Adjusted EPS, non-GAAP h $ 0.06 $ 0.19 $ 0.04 Expand Cross Country Healthcare, Inc. Consolidated Balance Sheets (Unaudited, amounts in thousands) March 31, December 31, 2025 2024 Assets Current assets: Cash and cash equivalents $ 80,697 $ 81,633 Accounts receivable, net 219,789 223,238 Income taxes receivable 5,893 10,389 Prepaid expenses 8,295 7,848 Insurance recovery receivable 9,343 9,255 Other current assets 1,182 2,637 Total current assets 325,199 335,000 Property and equipment, net 28,117 28,850 Operating lease right-of-use assets 2,219 2,468 Goodwill 135,060 135,060 Other intangible assets, net 39,965 42,186 Deferred tax assets 8,804 8,104 Insurance recovery receivable 20,193 20,928 Cloud computing 11,358 10,846 Other assets 5,320 5,809 Total assets $ 576,235 $ 589,251 Liabilities and Stockholders' Equity Current liabilities: Accounts payable and accrued expenses $ 56,325 $ 64,946 Accrued compensation and benefits 50,056 47,646 Operating lease liabilities 1,687 2,089 Earnout liability — 4,411 Other current liabilities 980 1,310 Total current liabilities 109,048 120,402 Operating lease liabilities 1,623 1,782 Accrued claims 33,982 34,425 Uncertain tax positions 10,168 10,117 Other liabilities 3,204 3,566 Total liabilities 158,025 170,292 Commitments and contingencies Stockholders' equity: Common stock 3 3 Additional paid-in capital 202,074 202,338 Accumulated other comprehensive loss (1,436 ) (1,441 ) Retained earnings 217,569 218,059 Total stockholders' equity 418,210 418,959 Total liabilities and stockholders' equity $ 576,235 $ 589,251 Expand Cross Country Healthcare, Inc. Summary Condensed Consolidated Statements of Cash Flows (Unaudited, amounts in thousands) Three Months Ended March 31, March 31, December 31, 2025 2024 2024 Net cash provided by operating activities $ 5,681 $ 6,011 $ 24,234 Net cash used in investing activities (1,886 ) (2,210 ) (2,531 ) Net cash used in financing activities (4,725 ) (15,653 ) (4,077 ) Effect of exchange rate changes on cash (6 ) — (14 ) Change in cash and cash equivalents (936 ) (11,852 ) 17,612 Cash and cash equivalents at beginning of period 81,633 17,094 64,021 Expand (a) Adjusted EBITDA, a non-GAAP financial measure, is defined as net income (loss) attributable to common stockholders before interest expense, income tax expense (benefit), depreciation and amortization, acquisition and integration-related (benefits) costs, restructuring (benefits) costs, legal and other losses, customer bankruptcy loss, impairment charges, gain or loss on derivative, loss on early extinguishment of debt, gain or loss on disposal of fixed assets, gain or loss on lease termination, gain or loss on sale of business, interest income, other expense (income), net, equity compensation, and system conversion costs. Adjusted EBITDA is not and should not be considered a measure of financial performance under GAAP. Management presents Adjusted EBITDA because it believes that Adjusted EBITDA is a useful supplement to net income (loss) attributable to common stockholders as an indicator of operating performance. Management uses Adjusted EBITDA for planning purposes and as one performance measure in its incentive programs for certain members of its management team. Adjusted EBITDA, as defined, closely matches the operating measure as defined by the Company's credit facilities. Adjusted EBITDA Margin is calculated by dividing Adjusted EBITDA by the Company's consolidated revenue. (b) Acquisition and integration costs relate primarily to fees associated with the pending Aya Merger. (c) Restructuring costs were primarily comprised of employee termination costs, lease-related exit costs, and reorganization costs as part of planned cost savings initiatives. (d) Includes legal costs and other settlement charges as presented on the consolidated statements of operations and losses pertaining to matters outside the normal course of operations. The Company incurred a settlement expense of $1.2 million, and recorded a $1.8 million recovery related to a previous loss, in the fourth quarter of 2024. During the first quarter of 2024, the Company recorded legal and other losses of $3.7 million representing an offer to settle a lawsuit, as well as estimated costs related to an unrecoverable asset. (e) Impairment charges for the three months ended March 31, 2024 and December 31, 2024 were related to right-of-use assets and related property in connection with vacated leases in those periods. Impairment charges for the three months ended December 31, 2024 also included the write-off of goodwill and intangible assets associated with the impairment of a previous asset acquisition. (f) Interest income for the three months ended March 31, 2025 and December 31, 2024 related to higher average cash on hand with higher available interest rates. (g) System conversion costs include enterprise resource planning system costs related to the upgrading and integrating of our middle and back-office platforms, with certain development costs capitalized and amortized in accordance with the Company's policies. (h) Adjusted EPS, a non-GAAP financial measure, is defined as net income (loss) attributable to common stockholders per diluted share before the diluted EPS impact of acquisition and integration-related (benefits) costs, restructuring (benefits) costs, legal and other losses, customer bankruptcy loss, impairment charges, gain or loss on derivative, loss on early extinguishment of debt, gain or loss on sale of business, system conversion costs, and nonrecurring income tax adjustments. Adjusted EPS is not and should not be considered a measure of financial performance under GAAP. Management presents Adjusted EPS because it believes that Adjusted EPS is a useful supplement to its reported EPS as an indicator of operating performance. Management believes Adjusted EPS provides a more useful comparison of the Company's underlying business performance from period to period and is more representative of the future earnings capacity of the Company than EPS. Quarterly non-GAAP adjustment may vary due to rounding. (i) Segment data is provided in accordance with the Segment Reporting Topic of the Financial Accounting Standards Board Accounting Standards Codification. (j) Contribution income is defined as income (loss) from operations before depreciation and amortization, acquisition and integration-related (benefits) costs, restructuring (benefits) costs, legal and other losses, impairment charges, and corporate overhead. Contribution income is a financial measure used by management when assessing segment performance. (k) Corporate overhead includes unallocated executive leadership and other centralized corporate functional support costs such as finance, IT, legal, human resources, and marketing, as well as public company expenses and Company-wide projects (initiatives). (l) Legal and other losses (gains) include legal costs and other settlement charges as presented on the consolidated statements of operations and losses pertaining to matters outside the normal course of operations. (m) Gross profit is defined as revenue from services less direct operating expenses. The Company's gross profit excludes allocated depreciation and amortization expense. Gross profit margin is calculated by dividing gross profit by revenue from services. (n) FTEs represent the average number of Nurse and Allied Staffing contract personnel on a full-time equivalent basis. (o) Average revenue per FTE per day is calculated by dividing Nurse and Allied Staffing revenue, excluding permanent placement, per FTE by the number of days worked in the respective periods. (p) Days filled is calculated by dividing the total hours invoiced during the period, including an estimate for the impact of accrued revenue, by 8 hours. Expand
Yahoo
05-05-2025
- Business
- Yahoo
San Diego-based Aya Healthcare announces death of founder Alan Braynin
SAN DIEGO (FOX 5/KUSI) — Alan Braynin, the founder and CEO of Aya Healthcare, has passed away, a spokesperson for company announced on Monday. The company is a leading travel nurse staffing and workforce solutions enterprise based in San Diego. Specifically, Aya Healthcare provides a platform that connects healthcare facilities with clinicians, offering various staffing options—from per diem to permanent hiring. According to the spokesperson, Braynin will be remembered as a visionary entrepreneur, philanthropist and transformative figure in the healthcare industry. Under his leadership, Aya Healthcare grew into one of the largest healthcare staffing firms in the United States, helping to connect hospitals with much-needed healthcare professionals during critical times—such as the COVID-19 pandemic. Kaiser Permanente, union settle strike with tentative deal Braynin founded the company in 2001 with the goal of reimagining how hospitals staffed their care teams. With a focus on technology, efficiency, and people-first values, Aya Healthcare has became a major player in an increasingly vital industry. 'Alan's innovations across business and healthcare improved countless lives and communities,' the spokesperson noted. 'His legacy of passion, brilliance and kindness will continue to impact all who knew him.' No details regarding the cause of his death were immediately provided. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
21-03-2025
- Health
- Yahoo
Aya Locums' Nurse Practitioner Named "2024 Locum Tenens Providers of the Year" by Locumpedia
SAN DIEGO, March 21, 2025--(BUSINESS WIRE)--Locumpedia named Emma Moore, Family Nurse Practitioner (NP) with Aya Locums, as a "2024 Locum Tenens Provider of the Year." Now in its third year, this award celebrates the dedication, excellence and impact of locum tenens physicians across the United States, and honors providers who deliver high-quality patient care on an as-needed basis to communities in need. Originally from West Virginia, Emma left all comforts of home to travel across the country to help communities in the Pacific Northwest. She's worked in a community health system as well as a rural clinic in a small town, where she became a lifeline for a population with limited healthcare access. "I chose to be an Aya locum because I'm given opportunities to learn about different patient populations in various regions while gaining clinical experience," Emma shared. "I love being a resource to facilities and patients, and filling staffing gaps where they exist. It's fun to experience new communities and have dedicated time off between contracts." Aya Locums is a division within Aya Healthcare that matches physicians and advanced practice providers with facilities across the country. The U.S. Bureau of Labor Statistics noted NPs are the fastest growing occupation in the country with a projected employment increase of 46% by 2031. "Emma is a standout locum provider who rises to every challenge, ensuring every patient benefits from her dedicated care and vast expertise," said Rhianna Watson, Associate VP of Recruitment at Aya Locums. "Emma's ability to adapt and deliver high-quality care in high-pressure environments is truly outstanding, epitomizing the very essence of an Aya Locum." To learn more about Aya Locums or to hear how individuals like Emma care for communities, visit About Aya Healthcare: Aya Healthcare is the largest healthcare talent software and staffing company in the United States. Aya operates the world's largest digital staffing platform delivering every component of healthcare-focused labor services, including travel nursing and allied health, per diem, permanent staff hiring, interim leadership, locum tenens and non-clinical professionals. Aya's AI-enabled software solutions, which include vendor management, float pool technology, provider solutions and predictive analytics, combined with its digital talent marketplaces, provide hospital systems greater efficiencies, superior operating results and reduced labor costs. While technology drives efficiency and scale, Aya's 6,000+ global employees power the company to deliver unparalleled accountability and exceptional experiences for clients and clinicians. Aya's company culture is rooted in giving back and supports organizations around food security, education, healthcare, safe shelter and equity. To learn more about Aya Healthcare, visit View source version on Contacts Rebecca KelleyPublic Relations ManagerAya 619.384.5269 Sign in to access your portfolio
